Objective. To describe the quality assurance activities related to follow-up evaluation of abnormal screening mammograms and subsequent initial treatment of women determined to have breast cancer for the screening programs represented in the International Breast Cancer Screening Network (IBSN).
Diagram of the screening mammography process, including follow-up and treatment. Adapted with permission from Klabunde et al. [15] .
screening as well as to receipt of state-of-the-art treatment, benefit. In recognition of this vital role, the International Breast Cancer Screening Network (IBSN), a voluntary concountries engaging in such evaluation require comprehensive data on all aspects of the breast cancer early detection sortium of 25 countries with population-based breast cancer screening programs, undertook an assessment of the scope continuum, from screening to follow-up of abnormal results and treatment of identified breast cancers. For these reasons, of quality assurance activities for screening mammography across member countries in 1998. The goal of the IBSN is population-based screening mammography is best viewed as a process that extends beyond the mammography examination to obtain and analyze data on the policies, administration, performance, and outcomes of population-based breast canitself to include follow-up of women with abnormal results and, if cancer is detected, assessment of treatment received cer screening. Descriptions of the organization, funding, coverage policies, and operating procedures for the screening (Figure 1 ). Furthermore, evaluation of program performance and impact requires data on cancer outcomes which ideally programs in IBSN countries have been published elsewhere [13, 14] . The quality assurance assessment consisted of four are obtained through access to a high-quality cancer registry operating within the geographic region targeted by the screen-major components: organization of quality assurance, technical quality control, quality assurance in follow-up and initial ing program [2] .
Defined as a system of procedures, checks, audits, and treatment, and quality assurance for data collection systems. Each component is summarized in a separate paper [15] [16] [17] . corrective actions to ensure that health services and reporting activities are of the highest achievable quality [12] , quality This report describes the quality assurance activities related to follow-up diagnostic evaluation of abnormal screening assurance is crucial in achieving optimal screening program mammograms and subsequent initial treatment of women centralized statistical center. Investigators in this mammography registry system are evaluating mammography perdetermined to have breast cancer for the screening programs represented in the IBSN. Both the extent to which quality formance and outcomes within defined populations, an objective common to all of the screening programs repassurance activities include processes of care and the collection and evaluation of data are considered. The assessment resented in the IBSN. While the facilities providing data to the registry system are not a census of all facilities, they are covers the major themes of organization of screening, assuring quality in the follow-up of abnormal screening mammograms, generally representative of screening mammography practice in the United States and cover diverse geographical regions and accessibility of data on initial treatment and tumor characteristics.
in the country. Completed questionnaires were received from all 23 countries. Data were coded and entered into a Microsoft Access database. Responses were reviewed by the working group Methods in October 1998. After clarification of missing or unclear responses by re-contacting each country's IBSN rep-A working group comprised of IBSN representatives from resentative as needed, responses were finalized in December eight countries was formed in October 1997 to develop 1998. Because the Republic of Ireland was in the process of and implement the quality assurance assessment. Between developing a new national breast cancer screening program November 1997 and April 1998, the working group conafter concluding a pilot program, Ireland's response is exstructed a comprehensive questionnaire designed to assess cluded from this report due to incomplete data. the following aspects of screening mammography quality
Comparisons were made between seven countries with assurance: organization of quality assurance; site visits and population-based screening programs that are national in accreditation; quality control; quality assurance for data sysscope and 13 countries with screening programs that are tems; quality assurance in follow-up and initial treatment; more locally organized. In some cases, these are pilot programs and program performance and impact measures. Existing that eventually may be expanded to encompass a larger screening mammography guidance documents addressing geographical area within the country. For example, data quality assurance [2, [18] [19] [20] were consulted in the developprovided for Japan reflect the pilot program in Miyagi prement of the questionnaire. The section on quality assurance fecture; implementation of a national screening mamin follow-up and initial treatment included questions about mography program began in Japan in 2000. Data for Germany program policies, standards, and procedures in general, as are included in this report, although it should be noted that well as those specific to surgical evaluation, cytology, and a population-based screening program was in the planning pathology. Items asking about calculation of measures to and implementation stages in Germany at the time of the evaluate the adequacy of follow-up and access to data on survey. As described above, data for the United States reptreatment and tumor characteristics also were included. Thus, resent an organized mammography registry system, and are the questionnaire section on quality assurance in follow-up summarized separately. and initial treatment covered activities related to both proNearly all of the countries with organized screening mamcesses of care and the collection and evaluation of data. mography programs also have opportunistic screening. HowQuestionnaire drafts were reviewed by working group ever, because few of these countries collect or assess data members and experts in screening mammography and queson opportunistic screening, it is impossible to summarize tionnaire design. The finalized questionnaire was mailed in opportunistic screening practice. Therefore, most countries late May 1998 to IBSN representatives in the 23 countries are not able to examine cancer outcomes among women who participating in the IBSN at that time. Representatives from are diagnosed outside of organized screening programs. In countries with organized screening programs and opthis assessment, we report data obtained from organized portunistic screening (i.e. screening occurring outside of screening programs and registries, the only data currently organized programs) were asked to respond for the quality available for international comparisons of screening mammeasures of their organized programs. Representatives from mography practice. countries with multiple organized screening programs were asked to provide, if possible, a summary response that reflected the majority of programs. Because the United States does not have an organized national or regional screening Results program comparable to those found in many European and other countries with more centralized health care systems, Characteristics of the screening mammography programs in the 22 responding countries are displayed in Table 1 . All the questionnaire was sent to a representative from the National Cancer Institute (NCI) who is responsible for a countries except Belgium and the United States reported having one or more organized programs designed to screen program of surveillance research focusing on communitybased screening mammography within a multi-region, or-a designated target population in a systematic fashion. The
Belgian program represented in this paper covers the city of ganized mammography registry system [21] . Thus, data for the United States reflect a diverse subset of health care Brussels and the region of Wallonia; an organized, populationbased screening program encompassing all of Belgium began facilities engaged in screening mammography and contributing data on mammography practice and outcomes to a implementation in 2001. As indicated by the number of programs, mammography facilities, X-ray units, and the proFourteen countries (64%) require accreditation of the cytology or pathology laboratories that analyze breast speciportion of the target population reached, screening programs vary considerably in size and scope. Furthermore, a variety mens, or subject pathology laboratories to periodic external audits (Table 4) . Four countries (Australia, Netherlands, of approaches to implementing quality assurance for these programs is evident, with nine countries doing so on a United Kingdom, United States) have all three of these quality assurance mechanisms in place; seven (Belgium, Denmark, national basis, seven subnationally, and four using a combined national/subnational approach. In two countries (Belgium Portugal, Sweden, Greece, Hungary, Japan) require accreditation of cytology and pathology laboratories but not and Uruguay), screening mammography quality assurance is the responsibility of the individual mammography facilities. external audits of pathology laboratories; two (Spain, Germany) subject pathology laboratories to periodic external All but three countries (Belgium, Greece, and Hungary) have established linkages between screening program and cancer audits; and one (Uruguay) requires accreditation of pathology laboratories. The remaining eight countries (Finland, Iceland, registry data, an important requirement for assessing program performance and impact [6] . In about half of these countries, Israel, Luxembourg, Canada, France, Italy, Norway) do not have quality assurance requirements specific to cytology and though, the linkage is not fully computerized.
pathology laboratories. All countries, however, indicated that screening programs have access to cytology and pathology Assuring quality in the follow-up of abnormal data on breast lesions, and all but one (Portugal) reported screening mammograms that screening program staff must actively obtain these data, Sixteen countries (73%) reported that the screening mam-although in about two-thirds of the countries, cytology and mography program is responsible for carrying out the follow-pathology reports are also routinely forwarded to the screening up diagnostic evaluation of an abnormal mammogram (Table program, thereby somewhat lessening the program's data 2). In the six countries in which screening mammography collection burden. programs do not have this responsibility (Israel, The NethCountries reported that screening programs use a variety erlands, Belgium, Canada, Uruguay, United States), women of measures and procedures to evaluate the adequacy of with an abnormal mammogram are either referred to ded-follow-up to an abnormal mammogram (Table 5 ). All counicated assessment centers or to their primary physician for tries calculate and monitor a recall rate for their programs. further evaluation. Fifteen countries (68%) indicated that they Seventeen (77%) convene multi-disciplinary case conferences have a written policy or guideline that delineates the steps to review abnormal screening mammograms that subto be taken to ensure follow-up of an abnormal mammogram. sequently are determined to be breast cancer, with 14 of Fourteen countries (64%) have established standards for the these including a radiologist, pathologist, and surgeon in the percentage of all screening mammograms that are deemed case conference. Seventeen (77%) actively assess a benignto be abnormal; these standards range from 5-7% for all to-malignant biopsy ratio, while the remaining five countries screens, 2-10% for first screens, and 1-7% for subsequent indicated that they have the data to do so although they do screens. Slightly over half (55%) of the countries have a not currently assess this measure. Thirteen countries (59%) specified time limit for follow-up of an abnormal mam-assess the sensitivity of screening mammography, with another mogram; the time limit varied from 1 week (Denmark, six reporting that they could calculate this measure although Norway) to 1 month (Belgium, Spain, Greece, Japan, Uru-they do not do so at present. Sixteen countries (73%) specify guay). Five countries (23%) have established standards for a a target breast cancer detection rate, and all but one (Uruguay) minimum percentage of abnormal mammograms that should assess the rate of interval cancers. Seventeen (77%) conduct have follow-up with fine needle aspiration, core biopsy, radiological reviews of interval cancers. or open biopsy; of these countries, only Norway specifies standards for all three procedures.
Access to data on initial treatment and tumor All countries reported having a set procedure for initiating characteristics surgical evaluation of women with abnormal mammograms (Table 3) . Requiring the woman with an abnormal screen to Eighteen of the 22 countries (82%) indicated that they are able to access data on surgery, radiation therapy, chemotherapy, contact the surgeon's office to arrange evaluation is a more commonly used procedure (13 countries) than direct contact hormonal therapy, tumor size, and lymph node involvement for women with abnormal mammograms who are diagnosed of the surgeon's office by screening program staff (11 countries) or direct evaluation by a surgeon in the screening with breast cancer (Table 6 ). However, in nearly half of these countries (44%), access to data on adjuvant therapy (i.e. program (seven countries). Furthermore, as can be seen in Table 3 , some countries use more than one mechanism for radiation therapy, chemotherapy, hormonal therapy) was reported to be with at least some difficulty. Only one country initiating surgical evaluation. In all countries, open biopsies are performed by surgeons, and in two, physicians other than (Belgium) indicated that the screening program does not obtain data on either initial treatment or tumor characteristics. surgeons also perform open biopsies: Uruguay (radiologists) and the United States (family physicians in certain rural areas). Two countries (United Kingdom, Canada) obtain data on surgery but not adjuvant therapy, while three (Finland, Canada, Five countries (23%) indicated that physicians who perform open biopsies are required to have certification in this pro-Denmark) do not obtain data on nodal involvement.
Of the 21 countries that reported having access to data cedure. Percentage target population: the proportion of the national population of women deemed eligible to attend for screening and covered by organized screening programs within the country.
2
Mammography facility: a location at which women obtain screening mammography. Contains one or more X-ray units plus the staff required to perform the procedure. Data for the screening program or mammography registry system are linked to cancer registry data.
5
Linkage of screening and cancer registry data is computerized. 6 Countries in which screening mammography quality assurance is required by law.
7
Linkage of screening and cancer registry data is manual. 8 Year implemented and percentage of target population covered by organized screening are blank because at the time of the survey, Belgium and the United States had not implemented organized, population-based screening programs.
9
Countries with a decentralized (subnational) organization of screening mammography, but in which the totality of organized screening programs attains national coverage.
10
Program in implementation phase.
11
The number of geographical regions participating in the mammography registry program. The screening program also monitors compliance with the time limit. 2 Countries with a decentralized (subnational) organization of screening mammography, but in which the totality of organized screening programs attains national coverage.
3
Program in implementation phase. Countries with a decentralized (subnational) organization of screening mammography, but in which the totality of organized screening programs attains national coverage. 2 Program in implementation phase.
In Uruguay, radiologists but not surgeons are required to be certified in breast surgery. Recall rate: the number of women who are asked to return to the screening unit (i.e. who are physically recalled) for a repeat mammogram due to a technical inadequacy of the screening mammogram (e.g. technical recall), or clarification of a perceived abnormality detected at the screening examination (e.g. recall for further assessment) per women screened.
2
Benign/malignant ratio: the ratio of pathologically proven benign to malignant lesions surgically removed in any round of screening.
3 Sensitivity: the ratio of histologically proven malignancies correctly identified at the screening examination to histologically proven malignancies identified and not identified at the screening examination (i.e. true positives/true positives + false negatives).
4
Cancer detection rate: the number of breast cancers detected per 1000 women screened.
5
Countries with a decentralized (subnational) organization of screening mammography, but in which the totality of organized screening programs attains national coverage. 6 Program in implementation phase. Screening programs in these countries do not obtain data on nodal assessment.
3
Screening program does not obtain data on surgery.
4
5
on surgery, all but three (Finland, Portugal, Hungary) indicated investigation of abnormal results, requiring accreditation or that screening program staff actively seek these data, although external audits of cytology and pathology laboratories, and about half of the countries noted that surgical reports are conducting case conferences to review abnormalities that are also routinely forwarded to the screening program. Among subsequently determined to be breast cancer. Another nine the countries that obtain data on tumor characteristics (i.e. concerned collection of data on follow-up of abnormal assessments of tumor size and nodal status), pathological screening mammograms such as assessing the recall rate, analysis was more often cited as the source of these data benign-to-malignant biopsy ratio, cancer detection rate, and than was clinical assessment. interval cancer rate. On average, countries reported having five of the processes of care measures and seven of the data collection measures in place. This finding may reflect differences in screening program organization, as programs
Discussion
in slightly over one-quarter of the countries reported not having responsibility for carrying out the follow-up of an Quality assurance involves an ongoing process of monitoring abnormal mammogram. It may also be an indication of the health services to ensure the provision of appropriate care influence of quality assurance guidance documents, especially that contributes to desired outcomes [22] . In screening mamthe European Guidelines for Quality Assurance in Mammography, population-based programs strive to demonstrate mography Screening [2] , which place greater emphasis on the a reduction in breast cancer mortality in the screened popudata that programs should collect to monitor follow-up and lation by attempting to identify a high proportion of the initial treatment than on specifying activities for ensuring highbreast cancer extant in the target population, optimize the quality processes of care in follow-up and initial treatment. rates of referral for follow-up diagnostic evaluation, and However, it is important to point out that we do not know detect a high proportion of breast cancers with small tumor which quality assurance mechanisms are associated with size and no nodal involvement [23] . Attainment of these optimal screening mammography program performance. Furgoals necessitates careful attention to the processes of care thermore, because the questionnaire that comprised the data involved in screening delivery, as well as the collection and source for this report covered multiple aspects of screening evaluation of data on screening delivery and outcomes. In mammography quality assurance, we were limited in the particular, programs must ensure not only high standards for number of items that could be included on the topic of screening but also that women with abnormal mammograms quality assurance in follow-up and initial treatment. For receive appropriate and timely follow-up diagnostic evaluation example, monitoring the recall rate is at best an indirect means and, if cancer is detected, high-quality treatment.
of assessing whether women with abnormal mammograms We assessed the extent to which the quality assurance receive appropriate follow-up and initial treatment. A 'time activities of the screening mammography programs repto follow-up' or 'lost to follow-up' measure might be more resented in the IBSN extend to follow-up of abnormal informative. The rate of screen-detected, in situ breast cancers mammograms and, when breast cancer is identified, initial is also an important measure of program performance; howtreatment. We examined approximately 22 different activities ever, these measures were not captured in our assessment. and measures addressing procedures and processes for followLikewise, we did not evaluate whether and how individual up of abnormal mammograms, and data collected on followcountries respond when screening mammography programs up and initial treatment to facilitate evaluation of screening do not adhere to defined quality standards. outcomes and program impact. Results show that all countries Three countries appear to be particularly comprehensive have in place at least half of the quality assurance activities in their implementation of quality assurance mechanisms and measures considered in this evaluation, although there related to follow-up and initial treatment. Australia reported is variation in the extent to which these mechanisms have having all but one of the indicators considered in this been implemented. For example, four countries (Israel, Luxevaluation in place. Norway responded that it has imembourg, Belgium, Canada) have implemented approximately plemented all of the measures with the exception of achalf of the activities and measures, while nine countries creditation of cytology and pathology laboratories and external (Finland, Iceland, Netherlands, Denmark, France, Italy, Hunauditing of pathology laboratories. The United Kingdom gary, Uruguay, United States) have about two-thirds in place is noteworthy because, despite the size and considerable and another nine (Australia, United Kingdom, Norway, Porcomplexity of this national program, it too has implemented tugal, Spain, Germany, Sweden, Greece, Japan) have imnearly all of the quality assurance aspects we considered. All plemented three-quarters or more. Countries with nationally three countries have developed quality assurance guidelines organized screening programs did not appear to be more specific to their screening programs [15, 19, 20] . The United likely to have implemented these mechanisms than did counKingdom has been particularly active in this regard, having tries with programs that were organized more locally.
published separate sets of guidelines addressing quality asMost countries, however, appeared to place greater emsurance for cytology, pathology, and surgical services [24] [25] [26] . phasis on quality assurance activities for follow-up and initial
It should be noted that Canada has recently initiated efforts treatment that involve the collection and evaluation of data to develop and monitor quality assurance standards specific than the implementation of mechanisms addressing processes to follow-up and treatment [27] . of care. We considered that nine of the mechanisms reflected such processes of follow-up care as having time limits for Quality assurance in follow-up and treatment is integral to the goal of demonstrating a reduction in breast cancer mor-(Belgium), Edward Hendrick (USA), Carrie Klabunde (NCI, Study Coordinator), Gonzalo Pou (Uruguay), Vitor Rodrigues tality attributable to population-based screening programs. As stated in the European Guidelines [2] , 'a high quality (Portugal), Hélène Sancho-Garnier (France), Astrid Scharpantgen (Luxembourg), and Stephen Taplin (USA). The auscreening program can only lead to a long-term mortality reduction if the treatment of women detected at screening thors wish to thank Cindy Mattingly and James Cucinelli of Information Management Services, Inc. (Silver Spring, MD, is of equally high quality'. Activities and measures that most programs should have in place to evaluate program impact USA) for expert assistance with questionnaire design and database programming. Funding for this study was provided on mortality include monitoring the cancer detection rate, interval cancer rate, recall rate, benign to malignant biopsy by the NCI (Bethesda, MD, USA) . ratio, and size and nodal status of screen-detected tumors [23] . Furthermore, the most efficient means of accessing the cancer outcomes data necessary for such an evaluation usually References requires linkage to a cancer registry located in the region targeted by the screening program. The results of the IBSN
